Physitrack Q2 2024: In line – Wellness holds back overall growth - Redeye
Redeye leaves its initial take on Physitrack’s Q2 figures, which overall was line with our expectations. Highlights include an annual recurring revenue (ARR) increase of 13% y/y and Software as a Service (SaaS) revenues now constituting 82% (71%) of total revenues. We anticipate moderate adjustments to our near-term estimates and fair value range.
Länk till analysen i sin helhet: https://www.redeye.se/research/1028534/physitrack-q2-2024in-line-wellness-holds-back-overall-growth?utm_source=finwire&utm_medium=RSS